Report cover image

Neurodegenerative Disease Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 127 Pages
SKU # APRC20542605

Description

Summary

According to APO Research, The global Neurodegenerative Disease market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Neurodegenerative Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Neurodegenerative Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Neurodegenerative Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Neurodegenerative Disease include Biogen Idec, Boehringer Ingelheim, Merck Serono, UCB, BORA PHARMACEUTICALS, Dongcheng Biochemicals, Ark Pharmaceutical, GlaxoSmithKline and Haisco Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disease.
The Neurodegenerative Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Neurodegenerative Disease Segment by Company

Biogen Idec
Boehringer Ingelheim
Merck Serono
UCB
BORA PHARMACEUTICALS
Dongcheng Biochemicals
Ark Pharmaceutical
GlaxoSmithKline
Haisco Pharmaceutical
Hisun Pharmaceutical
Huahai Pharmaceutical
Pfizer
Jingxin Pharmaceutical
Kanghong Pharmaceutical
Livzon Pharmaceutical
Luye Pharma
Novartis
Sanofi
TEVA
Neurodegenerative Disease Segment by Type

NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Disease Segment by Application

Alzheimer’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Parkinson’s Disease
Neurodegenerative Disease Segment by Application

Alzheimer’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Parkinson’s Disease
Neurodegenerative Disease Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neurodegenerative Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

127 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Neurodegenerative Disease by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 NMDA
2.2.3 SSRIs
2.2.4 Dopamine Inhibitors
2.3 Neurodegenerative Disease by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Alzheimer’s Disease
2.3.3 Huntington Disease
2.3.4 Amyotrophic Lateral Sclerosis
2.3.5 Parkinson’s Disease
2.4 Assumptions and Limitations
3 Neurodegenerative Disease Breakdown Data by Type
3.1 Global Neurodegenerative Disease Historic Market Size by Type (2020-2025)
3.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2026-2031)
4 Neurodegenerative Disease Breakdown Data by Application
4.1 Global Neurodegenerative Disease Historic Market Size by Application (2020-2025)
4.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Neurodegenerative Disease Market Perspective (2020-2031)
5.2 Global Neurodegenerative Disease Growth Trends by Region
5.2.1 Global Neurodegenerative Disease Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Neurodegenerative Disease Historic Market Size by Region (2020-2025)
5.2.3 Neurodegenerative Disease Forecasted Market Size by Region (2026-2031)
5.3 Neurodegenerative Disease Market Dynamics
5.3.1 Neurodegenerative Disease Industry Trends
5.3.2 Neurodegenerative Disease Market Drivers
5.3.3 Neurodegenerative Disease Market Challenges
5.3.4 Neurodegenerative Disease Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Neurodegenerative Disease Players by Revenue
6.1.1 Global Top Neurodegenerative Disease Players by Revenue (2020-2025)
6.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2020-2025)
6.2 Global Neurodegenerative Disease Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Neurodegenerative Disease Head Office and Area Served
6.4 Global Neurodegenerative Disease Players, Product Type & Application
6.5 Global Neurodegenerative Disease Manufacturers Established Date
6.6 Global Neurodegenerative Disease Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Neurodegenerative Disease Market Size (2020-2031)
7.2 North America Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Neurodegenerative Disease Market Size by Country (2020-2025)
7.4 North America Neurodegenerative Disease Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Neurodegenerative Disease Market Size (2020-2031)
8.2 Europe Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Neurodegenerative Disease Market Size by Country (2020-2025)
8.4 Europe Neurodegenerative Disease Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Neurodegenerative Disease Market Size (2020-2031)
9.2 Asia-Pacific Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Neurodegenerative Disease Market Size by Country (2020-2025)
9.4 Asia-Pacific Neurodegenerative Disease Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Neurodegenerative Disease Market Size (2020-2031)
10.2 South America Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Neurodegenerative Disease Market Size by Country (2020-2025)
10.4 South America Neurodegenerative Disease Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Neurodegenerative Disease Market Size (2020-2031)
11.2 Middle East & Africa Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Neurodegenerative Disease Market Size by Country (2020-2025)
11.4 Middle East & Africa Neurodegenerative Disease Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Biogen Idec
12.1.1 Biogen Idec Company Information
12.1.2 Biogen Idec Business Overview
12.1.3 Biogen Idec Revenue in Neurodegenerative Disease Business (2020-2025)
12.1.4 Biogen Idec Neurodegenerative Disease Product Portfolio
12.1.5 Biogen Idec Recent Developments
12.2 Boehringer Ingelheim
12.2.1 Boehringer Ingelheim Company Information
12.2.2 Boehringer Ingelheim Business Overview
12.2.3 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2020-2025)
12.2.4 Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
12.2.5 Boehringer Ingelheim Recent Developments
12.3 Merck Serono
12.3.1 Merck Serono Company Information
12.3.2 Merck Serono Business Overview
12.3.3 Merck Serono Revenue in Neurodegenerative Disease Business (2020-2025)
12.3.4 Merck Serono Neurodegenerative Disease Product Portfolio
12.3.5 Merck Serono Recent Developments
12.4 UCB
12.4.1 UCB Company Information
12.4.2 UCB Business Overview
12.4.3 UCB Revenue in Neurodegenerative Disease Business (2020-2025)
12.4.4 UCB Neurodegenerative Disease Product Portfolio
12.4.5 UCB Recent Developments
12.5 BORA PHARMACEUTICALS
12.5.1 BORA PHARMACEUTICALS Company Information
12.5.2 BORA PHARMACEUTICALS Business Overview
12.5.3 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2020-2025)
12.5.4 BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
12.5.5 BORA PHARMACEUTICALS Recent Developments
12.6 Dongcheng Biochemicals
12.6.1 Dongcheng Biochemicals Company Information
12.6.2 Dongcheng Biochemicals Business Overview
12.6.3 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2020-2025)
12.6.4 Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
12.6.5 Dongcheng Biochemicals Recent Developments
12.7 Ark Pharmaceutical
12.7.1 Ark Pharmaceutical Company Information
12.7.2 Ark Pharmaceutical Business Overview
12.7.3 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025)
12.7.4 Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
12.7.5 Ark Pharmaceutical Recent Developments
12.8 GlaxoSmithKline
12.8.1 GlaxoSmithKline Company Information
12.8.2 GlaxoSmithKline Business Overview
12.8.3 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2020-2025)
12.8.4 GlaxoSmithKline Neurodegenerative Disease Product Portfolio
12.8.5 GlaxoSmithKline Recent Developments
12.9 Haisco Pharmaceutical
12.9.1 Haisco Pharmaceutical Company Information
12.9.2 Haisco Pharmaceutical Business Overview
12.9.3 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025)
12.9.4 Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
12.9.5 Haisco Pharmaceutical Recent Developments
12.10 Hisun Pharmaceutical
12.10.1 Hisun Pharmaceutical Company Information
12.10.2 Hisun Pharmaceutical Business Overview
12.10.3 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025)
12.10.4 Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
12.10.5 Hisun Pharmaceutical Recent Developments
12.11 Huahai Pharmaceutical
12.11.1 Huahai Pharmaceutical Company Information
12.11.2 Huahai Pharmaceutical Business Overview
12.11.3 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025)
12.11.4 Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
12.11.5 Huahai Pharmaceutical Recent Developments
12.12 Pfizer
12.12.1 Pfizer Company Information
12.12.2 Pfizer Business Overview
12.12.3 Pfizer Revenue in Neurodegenerative Disease Business (2020-2025)
12.12.4 Pfizer Neurodegenerative Disease Product Portfolio
12.12.5 Pfizer Recent Developments
12.13 Jingxin Pharmaceutical
12.13.1 Jingxin Pharmaceutical Company Information
12.13.2 Jingxin Pharmaceutical Business Overview
12.13.3 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025)
12.13.4 Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
12.13.5 Jingxin Pharmaceutical Recent Developments
12.14 Kanghong Pharmaceutical
12.14.1 Kanghong Pharmaceutical Company Information
12.14.2 Kanghong Pharmaceutical Business Overview
12.14.3 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025)
12.14.4 Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
12.14.5 Kanghong Pharmaceutical Recent Developments
12.15 Livzon Pharmaceutical
12.15.1 Livzon Pharmaceutical Company Information
12.15.2 Livzon Pharmaceutical Business Overview
12.15.3 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025)
12.15.4 Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
12.15.5 Livzon Pharmaceutical Recent Developments
12.16 Luye Pharma
12.16.1 Luye Pharma Company Information
12.16.2 Luye Pharma Business Overview
12.16.3 Luye Pharma Revenue in Neurodegenerative Disease Business (2020-2025)
12.16.4 Luye Pharma Neurodegenerative Disease Product Portfolio
12.16.5 Luye Pharma Recent Developments
12.17 Novartis
12.17.1 Novartis Company Information
12.17.2 Novartis Business Overview
12.17.3 Novartis Revenue in Neurodegenerative Disease Business (2020-2025)
12.17.4 Novartis Neurodegenerative Disease Product Portfolio
12.17.5 Novartis Recent Developments
12.18 Sanofi
12.18.1 Sanofi Company Information
12.18.2 Sanofi Business Overview
12.18.3 Sanofi Revenue in Neurodegenerative Disease Business (2020-2025)
12.18.4 Sanofi Neurodegenerative Disease Product Portfolio
12.18.5 Sanofi Recent Developments
12.19 TEVA
12.19.1 TEVA Company Information
12.19.2 TEVA Business Overview
12.19.3 TEVA Revenue in Neurodegenerative Disease Business (2020-2025)
12.19.4 TEVA Neurodegenerative Disease Product Portfolio
12.19.5 TEVA Recent Developments
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Neurodegenerative Disease Market Size by Type (2020-2025) & (US$ Million)
Table 6. Global Neurodegenerative Disease Revenue Market Share by Type (2020-2025)
Table 7. Global Neurodegenerative Disease Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 8. Global Neurodegenerative Disease Revenue Market Share by Type (2026-2031)
Table 9. Global Neurodegenerative Disease Market Size by Application (2020-2025) & (US$ Million)
Table 10. Global Neurodegenerative Disease Revenue Market Share by Application (2020-2025)
Table 11. Global Neurodegenerative Disease Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 12. Global Neurodegenerative Disease Revenue Market Share by Application (2026-2031)
Table 13. Global Neurodegenerative Disease Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global Neurodegenerative Disease Market Size by Region (2020-2025) & (US$ Million)
Table 15. Global Neurodegenerative Disease Market Share by Region (2020-2025)
Table 16. Global Neurodegenerative Disease Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 17. Global Neurodegenerative Disease Market Share by Region (2026-2031)
Table 18. Neurodegenerative Disease Industry Trends
Table 19. Neurodegenerative Disease Industry Drivers
Table 20. Neurodegenerative Disease Industry Opportunities and Challenges
Table 21. Neurodegenerative Disease Market Restraints
Table 22. Global Top Neurodegenerative Disease Players by Revenue (US$ Million) & (2020-2025)
Table 23. Global Neurodegenerative Disease Revenue Market Share by Players (2020-2025)
Table 24. Global Neurodegenerative Disease Industry Players Ranking, 2023 VS 2024 VS 2025
Table 25. Global Key Players of Neurodegenerative Disease, Headquarters and Area Served
Table 26. Global Neurodegenerative Disease Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Neurodegenerative Disease by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. North America Neurodegenerative Disease Market Size by Country (2020-2025) & (US$ Million)
Table 32. North America Neurodegenerative Disease Market Size by Country (2026-2031) & (US$ Million)
Table 33. Europe Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Europe Neurodegenerative Disease Market Size by Country (2020-2025) & (US$ Million)
Table 35. Europe Neurodegenerative Disease Market Size by Country (2026-2031) & (US$ Million)
Table 36. Asia Pacific Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 37. Asia Pacific Neurodegenerative Disease Market Size by Region (2020-2025) & (US$ Million)
Table 38. Asia Pacific Neurodegenerative Disease Market Size by Country (2026-2031) & (US$ Million)
Table 39. South America Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 40. South America Neurodegenerative Disease Market Size by Country (2020-2025) & (US$ Million)
Table 41. South America Neurodegenerative Disease Market Size by Country (2026-2031) & (US$ Million)
Table 42. Middle East & Africa Neurodegenerative Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Middle East & Africa Neurodegenerative Disease Market Size by Country (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Neurodegenerative Disease Market Size by Country (2026-2031) & (US$ Million)
Table 45. Biogen Idec Company Information
Table 46. Biogen Idec Business Overview
Table 47. Biogen Idec Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 48. Biogen Idec Neurodegenerative Disease Product Portfolio
Table 49. Biogen Idec Recent Developments
Table 50. Boehringer Ingelheim Company Information
Table 51. Boehringer Ingelheim Business Overview
Table 52. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 53. Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
Table 54. Boehringer Ingelheim Recent Developments
Table 55. Merck Serono Company Information
Table 56. Merck Serono Business Overview
Table 57. Merck Serono Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 58. Merck Serono Neurodegenerative Disease Product Portfolio
Table 59. Merck Serono Recent Developments
Table 60. UCB Company Information
Table 61. UCB Business Overview
Table 62. UCB Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 63. UCB Neurodegenerative Disease Product Portfolio
Table 64. UCB Recent Developments
Table 65. BORA PHARMACEUTICALS Company Information
Table 66. BORA PHARMACEUTICALS Business Overview
Table 67. BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 68. BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
Table 69. BORA PHARMACEUTICALS Recent Developments
Table 70. Dongcheng Biochemicals Company Information
Table 71. Dongcheng Biochemicals Business Overview
Table 72. Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 73. Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
Table 74. Dongcheng Biochemicals Recent Developments
Table 75. Ark Pharmaceutical Company Information
Table 76. Ark Pharmaceutical Business Overview
Table 77. Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 78. Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
Table 79. Ark Pharmaceutical Recent Developments
Table 80. GlaxoSmithKline Company Information
Table 81. GlaxoSmithKline Business Overview
Table 82. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 83. GlaxoSmithKline Neurodegenerative Disease Product Portfolio
Table 84. GlaxoSmithKline Recent Developments
Table 85. Haisco Pharmaceutical Company Information
Table 86. Haisco Pharmaceutical Business Overview
Table 87. Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 88. Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
Table 89. Haisco Pharmaceutical Recent Developments
Table 90. Hisun Pharmaceutical Company Information
Table 91. Hisun Pharmaceutical Business Overview
Table 92. Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 93. Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
Table 94. Hisun Pharmaceutical Recent Developments
Table 95. Huahai Pharmaceutical Company Information
Table 96. Huahai Pharmaceutical Business Overview
Table 97. Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 98. Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
Table 99. Huahai Pharmaceutical Recent Developments
Table 100. Pfizer Company Information
Table 101. Pfizer Business Overview
Table 102. Pfizer Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 103. Pfizer Neurodegenerative Disease Product Portfolio
Table 104. Pfizer Recent Developments
Table 105. Jingxin Pharmaceutical Company Information
Table 106. Jingxin Pharmaceutical Business Overview
Table 107. Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 108. Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
Table 109. Jingxin Pharmaceutical Recent Developments
Table 110. Kanghong Pharmaceutical Company Information
Table 111. Kanghong Pharmaceutical Business Overview
Table 112. Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 113. Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
Table 114. Kanghong Pharmaceutical Recent Developments
Table 115. Livzon Pharmaceutical Company Information
Table 116. Livzon Pharmaceutical Business Overview
Table 117. Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 118. Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
Table 119. Livzon Pharmaceutical Recent Developments
Table 120. Luye Pharma Company Information
Table 121. Luye Pharma Business Overview
Table 122. Luye Pharma Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 123. Luye Pharma Neurodegenerative Disease Product Portfolio
Table 124. Luye Pharma Recent Developments
Table 125. Novartis Company Information
Table 126. Novartis Business Overview
Table 127. Novartis Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 128. Novartis Neurodegenerative Disease Product Portfolio
Table 129. Novartis Recent Developments
Table 130. Sanofi Company Information
Table 131. Sanofi Business Overview
Table 132. Sanofi Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 133. Sanofi Neurodegenerative Disease Product Portfolio
Table 134. Sanofi Recent Developments
Table 135. TEVA Company Information
Table 136. TEVA Business Overview
Table 137. TEVA Revenue in Neurodegenerative Disease Business (2020-2025) & (US$ Million)
Table 138. TEVA Neurodegenerative Disease Product Portfolio
Table 139. TEVA Recent Developments
Table 140. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Neurodegenerative Disease Product Image
Figure 5. Global Neurodegenerative Disease Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 6. Global Neurodegenerative Disease Market Share by Type: 2024 VS 2031
Figure 7. NMDA Product
Figure 8. SSRIs Product
Figure 9. Dopamine Inhibitors Product
Figure 10. Global Neurodegenerative Disease Market Size by Application (2025-2031) & (US$ Million)
Figure 11. Global Neurodegenerative Disease Market Share by Application: 2024 VS 2031
Figure 12. Alzheimer’s Disease Product
Figure 13. Huntington Disease Product
Figure 14. Amyotrophic Lateral Sclerosis Product
Figure 15. Parkinson’s Disease Product
Figure 16. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Neurodegenerative Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Neurodegenerative Disease Market Share by Region: 2024 VS 2031
Figure 19. Global Neurodegenerative Disease Market Share by Players in 2024
Figure 20. Global Neurodegenerative Disease Manufacturers Established Date
Figure 21. Global Top 5 and 10 Neurodegenerative Disease Players Market Share by Revenue in 2024
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. North America Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Neurodegenerative Disease Market Share by Country (2020-2031)
Figure 25. United States Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Mexico Neurodegenerative Disease Market Share by Country (2020-2031)
Figure 28. Europe Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Neurodegenerative Disease Market Share by Country (2020-2031)
Figure 30. Germany Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Spain Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Russia Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Netherlands Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Nordic Countries Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Neurodegenerative Disease Market Share by Country (2020-2031)
Figure 40. China Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Japan Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. South Korea Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. India Neurodegenerative Disease Market Share by Country (2020-2031)
Figure 45. Australia Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. China Taiwan Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. South America Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. South America Neurodegenerative Disease Market Share by Country (2020-2031)
Figure 50. Brazil Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Argentina Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Chile Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Colombia Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Peru Neurodegenerative Disease Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 56. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 57. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 58. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 59. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 60. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 61. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 63. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 64. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 65. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 66. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 67. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 68. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 69. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 70. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 71. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 72. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
Figure 73. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2020-2025)
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.